SK Life Science Labs Presents Groundbreaking Research in Molecular Glue Discovery at Keystone Symposia on Proximity-Based Therapeutics

KING OF PRUSSIA, Pa., February 28, 2025 – SK Life Science Labs, a subsidiary of SK Biopharmaceuticals Co., Ltd., a global biotech focused on the research, development, and commercialization of treatments for disorders of the central nervous system (CNS) and cancer, showcased its latest breakthrough in targeted protein degrader drug discovery research at the Keystone Symposia on Proximity-Based Therapeutics: Targeted Protein Degradation and Other Pharmacological Approaches in Santa Fe, NM, February 16-19.

"Our research findings mark a significant advance in molecular glue discovery by identifying new compounds that act as molecular glues in facilitating the degradation of targeted cancer-causing proteins," said Helai Mohammad, Ph.D., Chief Scientific Officer of SK Life Science Labs and a member of the research team. "Our novel precision medicine strategy is making significant contributions to the field of targeted protein degradation which holds tremendous promise for the development of new cancer therapeutics."

SK Life Science Labs' researchers presented two separate studies at the Keystone Symposia utilizing its proprietary Molecular Proximity Enabled Detection platform, known as MOPED™ Emerald. This innovative platform uses a highly sensitive assay that detects interactions between targeted proteins in large-scale screens to discover new molecular glues for defined drug targets and pre-selected E3s. E3s are proteins that play a key role in cancer development by regulating protein abundance and activity.

One study, *MOPED Emerald: A Novel Platform for Molecular Glue Discovery used to Identify CRBN-Based Degraders for IKZF3,* successfully demonstrated the platform's capabilities for detecting ternary complex formation between proteins with higher sensitivity than traditional assays. Among the approximately 500,000 compounds screened, seven potential new molecular glues were found that could facilitate the degradation of IKZF3 by binding it to CRBN through this novel high-throughput approach. The second study, *Identification of Novel p300 Molecular Glue Degraders Using MOPED Emerald*, identified 15 promising compounds from the half million screened, that can act as molecular glues for the degradation of the p300 protein, a key protein in various cancers. The identified glues utilize non-CRBN E3s, highlighting the broad E3 agnostic application for MOPED Emerald. By optimizing the compounds to form improved ternary complexes, the researchers successfully increased their potency and binding power.

"This research exemplifies SK Life Science Labs' drug discovery expertise. By identifying and optimizing new molecular glues, especially using E3s that have not been previously demonstrated to bind glues, we

are making substantial strides toward a new era of precision medicine that could offer more effective oncology treatments and improve patients' lives," said Dr. Mohammad.

###

About SK Life Science Labs

SK Life Science Labs, with headquarters in King of Prussia, Pennsylvania, is a U.S. subsidiary of **SK Biopharmaceuticals Co., Ltd.**, a pioneering South Korean company in drug development and commercialization. **SK Life Science Labs** (formerly Proteovant Therapeutics) exploits the ubiquitin-protease system (UPS) to discover and develop transformative medicines for the treatment of patients with life-altering diseases. Protein degradation harnesses the human body's innate cellular machinery by way of the UPS to identify and mark disease-causing proteins for destruction. This promising approach provides the opportunity to target proteins of interest, many of which were previously considered undruggable. SK Life Science Labs integrates its AI-enabled target ID platform, degrader drug-hunting expertise, and MOPED™ molecular glue screening platform to advance novel protein degraders. For more information, please visit www.sklslabs.com.

About SK Biopharmaceuticals Co., Ltd.

SK Biopharmaceuticals Co., Ltd. is part of SK Group, South Korea's second-largest conglomerate. SK Group is a collection of global industry-leading companies driving innovations in energy, advanced materials, biopharmaceuticals and digital business. For more information about SK Biopharmaceuticals, visit www.skbp.com/eng.

SK Biopharmaceuticals Co., Ltd. is part of **SK Group**, South Korea's second-largest conglomerate. **SK Group** is a collection of global industry-leading companies driving innovations in energy, advanced materials, biopharmaceuticals and digital business. Based in Seoul, **SK Group** invests in building sustainable businesses around the world with a shared commitment to reducing global greenhouse gas emissions. **SK Group** companies combined have $151 billion in global annual revenue and employ more than 100,000 people worldwide. SK Group is one of TIME's 100 Most Influential Companies of 2023. **SK Inc.**, the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, **SK Inc.** is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses. For more information about **SK Inc.**, visit https://sk-inc.com/en/main/mainpage.aspx. For more information about **SK Biopharmaceuticals**, visit www.skbp.com/eng.